241 related articles for article (PubMed ID: 21297430)
1. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.
Collier A; Ghosh S; McGlynn B; Hollins G
Am J Clin Oncol; 2012 Oct; 35(5):504-9. PubMed ID: 21297430
[TBL] [Abstract][Full Text] [Related]
2. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
3. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
7. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
Basaria S
J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
10. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
11. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
13. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
[TBL] [Abstract][Full Text] [Related]
14. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
Leahy Y
Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
16. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
17. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
Lage MJ; Barber BL; Markus RA
Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms.
Tivesten Å; Pinthus JH; Clarke N; Duivenvoorden W; Nilsson J
Urol Oncol; 2015 Nov; 33(11):464-75. PubMed ID: 26141678
[TBL] [Abstract][Full Text] [Related]
19. [Androgen deprivation and cardiovascular risk in prostate cancer treatment].
Leclercq C; Bouchot O; Azzouzi AR; Joly F; Miaadi N; Pfister C; Vincendeau S; de Crevoisier R
Prog Urol; 2012 Sep; 22 Suppl 2():S48-54. PubMed ID: 23098790
[TBL] [Abstract][Full Text] [Related]
20. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
